Friday, February 3, 2012

Early data show kidney cancer response to Exelixis' 'cabo'

Exelixis Inc.’s experimental cancer drug cabozantinib showed promise in patients with a form of metastatic kidney cancer, according to a preliminary report from an early-stage trial.
The South San Francisco-based drug developer (NASDAQ: EXEL), which will present the findings Saturday at the 2012 Genitourinary Cancers Symposium in San Francisco, said seven of 25 heavily pretreated patients with metastatic refractory renal cell carcinoma showed at least a partial response in the Phase Ib trial.
What’s more, 19 of 21 patients in the trial showed tumor regression after at least one assessment, the company said.

No comments:

Post a Comment